Last reviewed · How we verify
Dinoprostone 3 mg
At a glance
| Generic name | Dinoprostone 3 mg |
|---|---|
| Also known as | Dinoglandin® |
| Sponsor | Cairo University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers (PHASE1, PHASE2)
- Gemeprost Versus Dinoprostone in First Trimester Miscarriages (PHASE2)
- HTL0039732 in Participants With Advanced Solid Tumours (PHASE1, PHASE2)
- Dinoprostone Versus Vaginal Misoprostol for Induction of Labour (NA)
- What After the First Propess (PHASE2)
- Dienogest Versus GnRH-a Pre-treatment in Women With Endometriosis Undergoing IVF (NA)
- Effect of St. John's Wort and Olive Oils on the Postoperative Complications (PHASE4)
- Vaginal Dinoprostone Versus Isonicotinic Acid Hydrazide Prior to Diagnostic Office Hysteroscopy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dinoprostone 3 mg CI brief — competitive landscape report
- Dinoprostone 3 mg updates RSS · CI watch RSS
- Cairo University portfolio CI